Decorative dot pattern background image.
Decorative blue shape background image. Decorative blue shape background image. Decorative blue shape background image. Decorative blue shape background image.

Clinical Trials Search

As a clinical trial candidate at Methodist, you’re offered unique access to new drugs and technology being studied to improve patient outcomes.
Filter by Disease or Condition
Showing 41-50 results of 55
Head and Neck Cancer

NRG / HN011

Official Title: A Randomized Phase II Study of Nivolumab Versus Nivolumab and Relatlimab as Maintenance Treatment After First-Line Treatment with Platinum-Gemcitabine-Nivolumab for Patients with Epstein-Barr Virus-Associated Recurrent/Metastatic Nasopharyngeal Carcinoma (REMAIN)
Study Purpose: To determine if adding Relatlimab to Nivolumab maintenance therapy improves progression-free survival following first-line treatment of recurrent and/or metastatic nasopharyngeal carcinoma.
Status: Recruiting
Lung Cancer

NRG / LU007

Official Title: Testing The Addition Of Radiation Therapy To The Usual Immune Therapy Treatment (Atezolizumab) For Patients With Extensive Stage Small Cell Lung Cancer
Study Purpose: To determine if can we extend the time without your extensive small cell lung cancer growing or spreading by adding radiation therapy to the usual treatment for this type of cancer.
Status: Recruiting
Lung Cancer

NRG / LU008

Official Title: Phase III Prospective Randomized Trial of Primary Lung Tumor Stereotactic Body Radiation Therapy Followed By Concurrent Mediastinal Chemoradiation For Locally Advanced Non-Small Cell Lung Cancer 
Study Purpose: To compare overall survival in patients with Stage II-IIIC inoperable Non-small cell lung cancer comparing conventional radiation with chemotherapy  to stereotactic body radiation and conventional  radiation along with chemotherapy
Status: Recruiting
Gynecologic Cancer

NRG GY025

Official Title: A Randomized Phase II Trial of Nivolumab and Ipilimumab compared to Nivolumab Monotherapy in patients with deficient mismatch repair system recurrent endometrial carcinoma.
Study Purpose: To find out if combining two immunotherapy drugs, nivolumab and ipilimumab, is better or worse than the usual approach with a single immunotherapy agent.
Status: Recruiting
Skin Cancer

NRG HN014

Official Title: Randomized Phase III Trial of Neoadjuvant Immunotherapy With Response-Adapted Treatment Versus Standard-of-Care Treatment for Resectable Stage III/IV Cutaneous Squamous Cell Carcinoma 
Study Purpose: To test if giving immunotherapy before and after (in some cases) surgery extend the length of time without your cancer returning compared to the usual approach 
Status: Recruiting
Gynecologic Cancer

NRG-GY036

Official Title: A PHASE III TRIAL OF ONE VS. TWO YEARS OF MAINTENANCE OLAPARIB, WITH OR WITHOUT BEVACIZUMAB, IN PATIENTS WITH BRCA1/2 MUTATED OR HOMOLOGOUS RECOMBINATION DEFICIENT (HRD+) OVARIAN CANCER FOLLOWING RESPONSE TO FIRST LINE PLATINUM-BASED CHEMOTHERAPY
Study Purpose: To study if the use of Olaparib for one year keeps your ovarian cancer from growing or returning as well as the usual approach of two years.
Status: Recruiting
Breast Cancer

Personalis / 01-PS-001

Official Title: Breast Cancer-Minimal/Molecular Residual Disease Detection and Therapy Monitoring in Patients with Early Stage TNBC-Phase I (B-STRONGER-I)
Study Purpose: Evaluate the correlation of Minimal Residual Disease detection by NeXT Personal CTA (a molecular test) to pathological Complete Response (pCR) after neoadjuvant chemotherapy (NAC) in stage I-III triple negative breast cancer (TNBC)
Status: Recruiting
Heart and Vascular

ROMA WOMEN

Official Title: Randomized comparison of the clinical Outcome of single versus Multiple Arterial grafts: the ROMA trial
Study Purpose: It is the first cardiac surgery trial dedicated exclusively to women. Patients will be randomized in a 1:1 fashion. Patients will be randomized to a single arterial graft (SAG) or multiple arterial grafts (MAG).
Status: Recruiting
Sarcoma

Servier (IRIS) - CL3-95031-007

Official Title: A Phase 3, multicenter, double-blind, randomized, placebo-controlled study of ivosidenib in participants ≥18 years of age with locally advanced or metastatic conventional chondrosarcoma with an IDH1 mutation, untreated or previously treated with 1 systemic treatment regimen
Study Purpose: To assess how well the drug Ivosidenib works against chondrosarcoma
Status: Recruiting
Heart and Vascular

SHASTA-3

Official Title: DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 3 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF PLOZASIRAN IN ADULTS WITH SEVERE HYPERTRIGLYCERIDEMIA (SHASTA-3 STUDY)
Study Purpose: To demonstrate the efficacy of plozasiran on reducing fasting serum triglyceride levels.
Status: Recruiting